NEW YORK, April 7, 2015 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims on behalf of purchasers of the
securities of Cellular Biomedicine Group Inc. ("Cellular
Biomedicine Group" or the "Company") (NasdaqCM: CBMG -News).
Such investors are advised to contact Peretz Bronstein or his investor relations
coordinator Eitan Kimelman at
info@bgandg.com or 212-697-6484.
The investigation concerns whether Cellular Biomedicine Group
and certain of its officers and/or directors have violated Sections
10(b) and 20(a) of the Securities Exchange Act of 1934.
On April 7, 2015, Seeking
Alpha published a report on Cellular Biomedicine Group, which
asserts that: (i) it has achieved an unsustainable valuation with
paid stock promotion; (ii) its "CAR-T" technology has experienced
patient deaths and is worthless; (iii) its founders face multiple
allegations of dishonesty and are responsible for an alleged
illegal offshore stem cell clinic; and (iv) it has multiple
accounting and financial integrity issues. On this news, shares of
Cellular Biomedicine Group fell sharply during intraday trading on
April 7, 2015.
Following this news, shares of Cellular Biomedicine Group fell
$7.40, or 22.95%, during intraday
trading to trade at $24.83.76 on
April 7, 2015
If you are aware of any facts relating to this investigation, or
purchased shares of Cellular Biomedicine Group , you can assist
this investigation by contacting Peretz
Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz &
Grossman, LLC at 212-697-6484 or via email info@bgandg.com.
Those who inquire by e-mail are encouraged to include their mailing
address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-cellular-biomedicine-group-inc-300062352.html
SOURCE Bronstein, Gewirtz & Grossman, LLC